United StatesDirects rescheduling review and expands CBD research and regulation
Could change how marijuana and hemp-derived CBD are researched, regulated, and accessed, affecting patient treatment options and product safety.
What it does
Directs the Attorney General to complete rulemaking to reschedule marijuana to Schedule III under the Controlled Substances Act.
Directs White House staff to work with Congress to revise the statutory definition and create a regulatory framework for hemp-derived cannabinoid (CBD) products, including THC per-serving guidelines and CBD:THC ratio considerations.
Tasks HHS, FDA, CMS, and NIH to develop research methods and models using real-world evidence to study medical marijuana and hemp-derived cannabinoid products and inform standards of care.
Argument forRescheduling to Schedule III could reduce legal obstacles and expand research, producing better evidence for medical uses and prescribing guidance.
Argument againstRescheduling could raise concerns that greater access increases misuse or public health harms if regulatory safeguards are delayed or insufficient.
Where do you stand?
Choose your position
Where it stands
- Signed
- Published
History
- 2025
- Dec 23Published in the Federal RegisterPublished
- Dec 18Signed by President Donald TrumpSigned
HealthcarePublic SafetyGovernment & Ethics